IQVIA HoldingsMEX:IQV 76 EBITDA Margin % is 19.47% as of Mar. 2026, which is 2% above its 10-year median of 19.11. GuruFocus rates MEX:IQV with a GF Score™ of 76/100 and a GF Value™ of MXN4,024.35 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, IQVIA Holdings ranks better than 76.47% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. IQVIA Holdings's EBITDA for the
three
months ended in Mar. 2026 was MXN14,570 Mil. IQVIA Holdings's Revenue for the
three
months ended in Mar. 2026 was MXN74,854 Mil. Therefore, IQVIA Holdings's EBITDA margin for the quarter that ended in Mar. 2026 was 19.47%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
IQVIA Holdings EBITDA Margin % Related Terms
IQVIA Holdings EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for IQVIA Holdings's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:IQV vs NTRA, ILMN, MTD: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, IQVIA Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IQVIA Holdings EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IQVIA Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where IQVIA Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IQVIA Holdings (MEX:IQV) has a EBITDA Margin % of 19.47% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on IQVIA Holdings and its competitors. This is near median its historical median of 19.11. Over the past decade, IQVIA Holdings' EBITDA Margin % has ranged from 12.46 to 22.41. According to the industry distribution chart, IQVIA Holdings ranks #48 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 23.5%.
Is IQVIA Holdings' EBITDA Margin % too high?
IQVIA Holdings' current EBITDA Margin % of 19.47% is near median its 10-year median of 19.11. Over the past 10 years, this metric has ranged from a low of 12.46 to a high of 22.41. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.20. IQVIA Holdings' value of 19.47% is 274.4% above this industry median. Based on the distribution chart, IQVIA Holdings ranks #48 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, IQVIA Holdings has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IQVIA Holdings' EBITDA Margin % compare to NTRA and ILMN?
According to the Medical Diagnostics & Research industry distribution chart, IQVIA Holdings ranks #48 out of 204 companies for EBITDA Margin %. This places IQVIA Holdings in the top 24% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 5.20. IQVIA Holdings' value of 19.47% is 274.4% above this benchmark. Historically, IQVIA Holdings' own EBITDA Margin % has ranged from 12.46 to 22.41 over the past decade. While the company's 10-year median is 19.11 vs. the industry median of 5.20, IQVIA Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IQVIA Holdings's current EBITDA Margin % of 19.47% is 274.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on IQVIA Holdings and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IQVIA Holdings's current EBITDA Margin % is 19.47%, which is near median its own 10-year median of 19.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IQVIA Holdings stock overvalued right now?
Based on GuruFocus' analysis, IQVIA Holdings (MEX:IQV) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN4,024.35, compared to a current price of MXN3,000.00 — trading 25.5% below its estimated fair value. The current EBITDA Margin % is 19.47%, which is near median its 10-year median of 19.11 and 274.4% above the Medical Diagnostics & Research industry median of 5.20. IQVIA Holdings' overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For IQVIA Holdings (MEX:IQV), the current EBITDA Margin % is 19.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IQVIA Holdings (MEX:IQV) Overvalued in 2026?
Based on GuruFocus' analysis, IQVIA Holdings stock appears to be undervalued.
The current stock price of MXN3,000.00 is trading 25.5% below its estimated GF Value™ of MXN4,024.35.
GuruFocus considers IQVIA Holdings to be Modestly Undervalued.
Key valuation signals for MEX:IQV:
EBITDA Margin %: 19.47% (near median its 10-year median of 19.11)
GF Value™: MXN4,024.35 vs. price of MXN3,000.00 (25.5% below fair value)
Industry Position: 274.4% above the Medical Diagnostics & Research median (#48 of 204)
No single metric tells the full story. See the MEX:IQV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
76GF Score
Get the complete analysis for MEX:IQV
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:IQV has been successfully added to your 
